Fong Clow
Corporate Officer/Principal bei SUMMIT THERAPEUTICS INC.
Profil
Fong Wang Clow is currently the Chief Biometrics Officer at Summit Therapeutics, Inc. Prior to this, Dr. Clow held the position of VP-Biostatistics Programming & Data Management at Pharmacyclics LLC.
Dr. Clow also served as Senior Vice President-Development at Novacea, Inc. from 2005 to 2009.
Dr. Clow received an undergraduate degree from Wuhan University and graduate and doctorate degrees from Harvard T.H.
Chan School of Public Health.
Aktive Positionen von Fong Clow
| Unternehmen | Position | Beginn |
|---|---|---|
| SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 16.10.2023 |
Ehemalige bekannte Positionen von Fong Clow
| Unternehmen | Position | Ende |
|---|---|---|
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Corporate Officer/Principal | 03.02.2009 |
| PHARMACYCLICS, INC. | Corporate Officer/Principal | - |
Ausbildung von Fong Clow
| Wuhan University | Undergraduate Degree |
| Harvard T.H. Chan School of Public Health | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SUMMIT THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
